Figure 2. KIR2DL5 was expressed on human innate and adaptive immune cells.

(A) KIR2DL5 expression on human PBMCs. Left: Flow cytometric analysis of KIR2DL5 expression on the indicated subsets from 1 donor. Right: The frequencies of KIR2DL5⁺ cells in the indicated subsets (n = 17 for NK and CD8⁺ T; n = 15 for CD4⁺ T and γδ T). Data are represented as mean ± SEM. (B) Left: The distribution of KIR2DL5⁺ CD8⁺ T cells on the indicated cell subsets based on CD45RA and CCR7 expression. Right: Summary of KIR2DL5⁺ CD8⁺ T cell distribution (n = 8). Data are represented as mean ± SEM. (C) KIR2DL5 expression on CD56^brightCD16^– and CD56^dimCD16⁺ NK subsets. The frequencies of KIR2DL5⁺ cells on the indicated NK cell subsets are shown on the right (n = 8). (D) KIR2DL5 expression on CD56^dimCD57^– and CD56^dimCD57⁺ NK subsets. The frequencies of KIR2DL5⁺ cells on the indicated NK cell subsets (n = 8) are shown on the right. (E) Flow cytometric analysis of coexpression pattern of KIR2DL5 with DNAM-1, TIGIT, and CD96 on primary resting or IL-2+IL-15–activated NK cells. (F) The coexpression pattern of KIR2DL5 with other receptors on NK cells from human PBMCs. The t-SNE plots were generated based on spectral flow cytometric data (n = 3). In E, data are representative of 3 independent experiments with 3 different donors. P values were determined by 1-way ANOVA (A and B) or 2-tailed paired t test (C and D).